Alloy Therapeutics and Pyxis Oncology announced the formation of their joint venture, Kyma Therapeutics, which will develop immune-modulating antibodies in an attempt to tackle cancer and autoimmune diseases.

Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.

Blackstone Group Inc. is investing $400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer, the private equity giant’s largest-ever bet on drug development.

Swiss company Vifor Pharma and Germany’s Evotec AG launched a joint venture to focus on the discovery and development of new therapies for kidney diseases.

GlaxoSmithKline offered concessions to address EU antitrust concerns over the planned joint venture with Pfizer’s consumer health business, the European Commission said.

Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.

UnitedHealth Group’s Optum unit is suing David Smith, a former information technology executive, for breach of contract.

GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker’s chief executive officer said.

GlaxoSmithKline plans to split into two businesses – one for Rx drugs and vaccines, and the other for OTC products – after forming a new joint venture with Pfizer’s consumer health division.

For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.